Publications by authors named "Carles Escriu"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

153

Total Likes

216

Extended Reach

782,060

Social Features

87
S
Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis.
Alessandro Brunelli, Alessio Mariolo, Clemens Aigner, David Gomez De Antonio, Marcelo Jimenez, Carles Escriu

Eur J Cardiothorac Surg· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with Osimertinib plus Chemotherapy in -Mutated Advanced NSCLC.
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, James Chih-Hsin Yang, Ying Liu, Carles Escriu

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
Alessandro Brunelli, Ross Hoffman, Robin Wotton, Shobhit Baijal, Pooja Bhatnagar, Carles Escriu

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Igor Gomez-Randulfe, Sofía Silva Díaz, Carles Escriu, Saara Mohammed, Riyaz Shah

Ther Adv Med Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations.
Marcus Rathbone, Conor O'Hagan, Helen Wong, Adeel Khan, Timothy Cook, Carles Escriu

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Conor S Gillespie, Mohammad A Mustafa, George E Richardson, Ali M Alam, Keng Siang Lee, Carles Escriu

J Thorac Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Carles Escriu

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Carles Escriu

Int J Mol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Giuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, Judith Cave, Charles Comins, Carles Escriu

Int Immunopharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, Maximilian J Hochmair, Seung Hyeun Lee, Carles Escriu

Lung Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.
Masahiro Tsuboi, Walter Weder, Carles Escriu, Collin Blakely, Jianxing He

Future Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
Jason Lester, Carles Escriu, Sarah Khan, Emma Hudson, Talal Mansy

BMC Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.
Lee S Schwartzberg, Hidehito Horinouchi, David Chan, Sara Chernilo, Michaela L Tsai, Carles Escriu

NPJ Precis Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Mostafa Sallam, Helen Wong, Carles Escriu

BMC Pulm Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Alexander Haragan, John K Field, Michael P A Davies, Carles Escriu, Aaron Gruver

Lung Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.
Anne Y Warren, Charlie E Massie, Kate Watt, Katarina Luko, Folake Orafidiya, Carles Escriu

Oncogene· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.
Ramon Andrade De Mello, Carles Escriu, Pedro Castelo-Branco, Paloma Lucena Cabral, Giannis Mountzios

Oncotarget· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.
Carles Escriu, John K Field

J Thorac Dis· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse epigenetic strategies interact to control epidermal differentiation.
Klaas W Mulder, Xin Wang, Carles Escriu, Yoko Ito, Roland F Schwarz

Nat Cell Biol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis